MAP2K1 and neoplasm: Three MEK1/2 inhibitors, trametinib, cobimetinib, and binimetinib, are currently approved to treat advanced metastatic melanoma where the tumor has a B-Raf V600E/K mutation, with the aim of inhibiting the constitutively active Raf/Ras/MEK/ERK pathway.